Letters to the Editor

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
University of Arizona Cancer Center, Tucson, AZ
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Knight Cancer Institute, Oregon Health and Science University, Portland, OR; City of Hope Comprehensive Cancer Center, Duarte, CA
Haematologica Early view Jan 28, 2021 https://doi.org/10.3324/haematol.2020.270298